Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

clinical trial

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT02831179

P6099clinical trial phasephase I clinical trialQ5452194
P582end time2019-02-01
P1050medical conditioncarcinomaQ33525
gastrinomaQ786852
adrenocortical carcinomaQ918285
insulinomaQ1501239
VIPomaQ1518637
multiple endocrine neoplasiaQ1553018
somatostatinomaQ1736456
multiple endocrine neoplasia type 1Q3347154
Zollinger–Ellison syndromeQ218712
multiple endocrine neoplasia type 2AQ604075
multiple endocrine neoplasia type 2BQ624748
glucagonomaQ770843
P2899minimum age18
P1132number of participants0
P8329principal investigatorJordan D. BerlinQ91134026
P4844research interventionveliparibQ7919041
P580start time2017-12-01
P8363study typeinterventional studyQ78089383
P1476titleA Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors

Search more.